The whole blood loop assay

Since 2014, Immuneed has offered a unique, cost-effective, first-in-class extracorporeal whole blood loop assay. The assay measures drug-related rapid infusion reactions mediated by blood components, as well as drug biodistribution and mode-of-action studies. Our advanced characterization services are paired with our immunological know-how and expertise, enabling us to link pre-clinical data to clinical reality.

The whole-blood loop assay is applicable during drug discovery and development – from screening of drug candidates to early clinical development – and is suitable for various drug candidates, including biosimilars, antibodies, peptides and viruses. The assay setup is designed together with you and your team to enhance data output.

SIGN UP!

Are you interested in using our whole-blood loop model to assess toxicity or/and efficacy of your drug candidate?

Contact us to find out how we can help you!

I'm interested in






In order for us to get in touch with you we must store some of your data on our servers. Checking the 'I consent' box indicates that you have read our privacy policy which outlines how we process, protect and manage your data, and that you consent to us storing it in accordance with this policy.

I consent

NEWS

Accelerate your drug’s journey to the clinic. Seminar in Gothenburg, May 13.- Immuneed and CTC Clinical Trial Consultants will visit the major cities in Sweden for a joint seminar on how to manage risk and build value in early clinical development: “The Preclinical Human Model”. First out was Lund in March, and this seminar attracted many innovative biotech companies seeking to advance their current pipeline. Now we …
Seminar: “Manage risk and build value in early clinical development”- In a close partnership, Immuneed and CTC Clinical Trial Consultants offer a total solution for the preclinical and clinical characterisation of your drug. By using a unique approach, we help you manage risk and build value in your early clinical development. Join our seminar and learn more about the preclinical human model.
Atlas of Science published a summary of our Immuno-Service- Atlas of Science published a summary of our Immuno-Service. Functional and safety assessments of biologics prior to first-in-human (FIH) is key to understand the mode-of-action and safety profile. We have made use of an ex-vivo whole blood assay for its potential in assessment of antibody-based drug candidates. Read more: http://atlasofscience.org/profiling-biologics-in-circulating-human-whole-blood/